These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Another FDA warning: Kava supplements. Parkman CA Case Manager; 2002; 13(4):26-8. PubMed ID: 12131903 [No Abstract] [Full Text] [Related]
3. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(47):1065-7. PubMed ID: 12500906 [TBL] [Abstract][Full Text] [Related]
4. Kava: a supplement to avoid. Consum Rep; 2003 Mar; 68(3):8. PubMed ID: 12599340 [No Abstract] [Full Text] [Related]
5. Risk of kava hepatotoxicity and the FDA consumer advisory. Teschke R; Schulze J JAMA; 2010 Nov; 304(19):2174-5. PubMed ID: 21081732 [No Abstract] [Full Text] [Related]
6. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002. JAMA; 2003 Jan; 289(1):36-7. PubMed ID: 12515265 [No Abstract] [Full Text] [Related]
7. Dangerous supplements: still at large. Consum Rep; 2004 May; 69(5):12-7. PubMed ID: 15104077 [No Abstract] [Full Text] [Related]
11. Concerns over kava have the FDA's attention. Mayo Clin Health Lett; 2002 Jul; 20(7):4. PubMed ID: 12132472 [No Abstract] [Full Text] [Related]
12. Dangerous supplements: what you don't know about these 12 ingredients could hurt you. Consum Rep; 2010 Sep; 75(9):16-20. PubMed ID: 20712098 [No Abstract] [Full Text] [Related]
13. Problems with dietary supplements. Med Lett Drugs Ther; 2002 Sep; 44(1140):84-6. PubMed ID: 12360122 [No Abstract] [Full Text] [Related]
14. The curious case of Kava. Grossman L Time; 2002 Apr; 159(14):58. PubMed ID: 11951318 [No Abstract] [Full Text] [Related]
15. Sebotropic eruption associated with use of oral kava kava supplement. Huynh JC; Asgari MM; Moore MM Clin Exp Dermatol; 2014 Oct; 39(7):816-8. PubMed ID: 25214405 [TBL] [Abstract][Full Text] [Related]
16. Kava hepatotoxicity: a European view. Teschke R; Schwarzenboeck A; Akinci A N Z Med J; 2008 Oct; 121(1283):90-8. PubMed ID: 18841189 [TBL] [Abstract][Full Text] [Related]
17. Kava hepatotoxicity solution: A six-point plan for new kava standardization. Teschke R; Sarris J; Lebot V Phytomedicine; 2011 Jan; 18(2-3):96-103. PubMed ID: 21112196 [TBL] [Abstract][Full Text] [Related]
18. A brief report of student research: mechanism of analgesic effect and efficacy and anesthesia interactions of kava in the male Sprague-Dawley rat. Sullivan J; Romm J; Reilly M Dimens Crit Care Nurs; 2009; 28(3):138-40. PubMed ID: 19387280 [TBL] [Abstract][Full Text] [Related]
19. Impact of federal safety advisories on health food store advice. Mills E; Singh R; Ross C; Ernst E; Wilson K J Gen Intern Med; 2004 Mar; 19(3):269-72. PubMed ID: 15009783 [TBL] [Abstract][Full Text] [Related]
20. Kava extract, an herbal alternative for anxiety relief, potentiates acetaminophen-induced cytotoxicity in rat hepatic cells. Yang X; Salminen WF Phytomedicine; 2011 May; 18(7):592-600. PubMed ID: 21397479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]